China Medical System Holdings Ltd banner
C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 1.56 EUR 12.23%
Market Cap: €6.4B

China Medical System Holdings Ltd
Cash Interest Paid

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Medical System Holdings Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
SWB:2M7C
Cash Interest Paid
¥20.3m
CAGR 3-Years
-19%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Cash Interest Paid
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Cash Interest Paid
HK$169.1m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
2%
Sino Biopharmaceutical Ltd
HKEX:1177
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Cash Interest Paid
HK$2B
CAGR 3-Years
1%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Cash Interest Paid
$2.5m
CAGR 3-Years
156%
CAGR 5-Years
25%
CAGR 10-Years
8%
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
6.4B EUR
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.

2M7C Intrinsic Value
1.16 EUR
Overvaluation 25%
Intrinsic Value
Price €1.56
C

See Also

What is China Medical System Holdings Ltd's Cash Interest Paid?
Cash Interest Paid
20.3m CNY

Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Cash Interest Paid amounts to 20.3m CNY.

What is China Medical System Holdings Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
-2%

Over the last year, the Cash Interest Paid growth was -47%. The average annual Cash Interest Paid growth rates for China Medical System Holdings Ltd have been -19% over the past three years , -6% over the past five years , and -2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett